Back

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy to improve outcomes in coronary disease Clinical ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Robert Rosenson

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

7 More presentations in this session

Presentation thumbnail
Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial
Doctor N. Kruger (Boston, US)
Abstract
Presentation thumbnail
AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies
Doctor J. Rosenmeier (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Side effects of low-dose colchicine in chronic coronary syndromes, the LoDoCo2 trial
Miss J. Jannink (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Colchicine in patients with recent myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Ms A. Moiz (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
PCSK-9 inhibitors vs. ezetimibe for secondary prevention: utilization disparities and clinical outcomes
Doctor M. Sghayyer (Birmingham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy to improve outcomes in coronary disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources